Global Autoimmune Disease Therapeutics Industry

• Publication date: October 2011

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Others. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis i...

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Others. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets.The report profiles 112 companies including many key and niche players such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck & Co., Inc, Merck Serono SA, Novartis AG, Sanofi-aventis SA , Shire Plc, Teva Pharmaceuticals Industries Limited, and UCB S.A. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Global Pathology Industry

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definition and Scope of Study 3
Rheumatoid Arthritis 4
Multiple Sclerosis 4
Psoriasis 4
Crohn's disease 4

2. INDUSTRY OVERVIEW & OUTLOOK 5
Autoimmune Disease Therapeutics Market Continues to Flourish 5
Pharmaceutical Industry Hit by Economic Downturn 5
Economic Downturn Takes Toll on R&D 6
Current and Future Analysis 6
Segment Analysis 6
Rheumatoid Arthritis Therapeutics - The Largest Segment 7
Multiple Sclerosis Therapeutics Market 7
Crohn’s Disease Therapeutics Market 7
Ulcerative Colitis Drugs Market 8

3. MARKET DYNAMICS AND TRENDS 9
Biologics Find Acceptance as First Line of Treatment for
Autoimmune Diseases 9
High Unmet Need Favors Growth 9
Impact of Biosimilars Legislation on Biologic Arthritis Drugs
Market 9
New Products to Drive Market Growth 10
Biogenerics to Expand Adoption of Biological Drugs 10
Risk of Cancer Due to Anti-TNF Drugs 11
Superior Outcomes to Enhance Adoption of Biologics 11
Efficacy and Convenience - Key Factors Driving Physician’s
Decision 11

4. DISEASE OVERVIEW 12
Immunity and Immune System 12
Autoimmune Diseases 12
Women- Highly Susceptible to Autoimmune Diseases 12
Table 1: Percentage Breakdown of Incidence of Autoimmune
Diseases in Men and Women (includes corresponding
Graph/Chart) 13
Complexity in Manifestations Renders Difficulty in
Understanding the Conditions 14
Etiology of Autoimmune Diseases 14
Genetic Predisposition 14
Environmental Factors 15
Autoimmune Diseases - A Social and Health Burden 15
Regulatory Glitches and High Costs Hinder Biogenerics 16
Types of Autoimmune Diseases 16
Incidence and Prevalence 17
Diagnosis and Treatment of Autoimmune Diseases 17
Overview on Select Biologic Drugs 17
Remicade 17
Humira 18
Rituxan® (rituximab) 18
Cimzia 19
Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market 20
Psoriasis - A Promising Market for Cimzia 20
Actemra 20
Enbrel 20

5. OVERVIEW OF SELECT AUTOIMMUNE DISEASES 21
Rheumatoid Arthritis 21
Disease Overview 21
Low Penetration to Sustain growth of Anti-TNF Drugs 21
Incidence and Prevalence Higher in Urban and Developed Regions 21
Symptoms and Diagnosis 22
Treatment of Rheumatoid Arthritis 22
BRMs Revolutionize RA Treatment 22
Branded Products 23
Drugs Used in Treating Rheumatoid Arthritis 23
Year of Approval of Leading Biologics in Rheumatoid
Arthritis Therapy 23
Key Drugs in Late Stage Development for Rheumatoid Arthritis
Treatment 24
Competitive Landscape 24
Table 2: Comparative Analysis of Leading Biologic Rheumatoid
Arthritis Drugs based on ACR Scores by End Point 25
High Prices and Safety Concerns 25
Multiple Sclerosis 25
Etiology 26
Types of Multiple Sclerosis 26
Table 3: Prevalence of Different Types of Multiple Sclerosis 27
Pathology 27
Prevalence of Multiple Sclerosis High in Women 27
Facts About Multiple Sclerosis 27
Treatment 28
Interferon Drugs - High Efficacy Drugs in Existing MS Therapies 28
Beta Interferon Drugs in Multiple Sclerosis Treatment 29
Non-Interferon Drugs 29
Non-Interferon Drugs in Multiple Sclerosis Treatment 29
Trends in Multiple Sclerosis Market 30
High Unmet Need and Rich Pipeline to Expand MS Market 30
Interferon-based Drugs Lead Multiple Sclerosis Drug Market 30
Oral Drugs Alter Dynamics in MS Therapies Market 31
Dip in Sales Inevitable for Current Therapies 31
Tough Times Ahead for Betaseron 32
Competitive Landscape 32
Table 4: Leading Products/Companies in the Global Multiple
Sclerosis Therapeutics Market (2010): Percentage Share
Breakdown of Value Sales for Biogen Idec,
Teva/sanofi-aventis*, Merck Serono, Bayer Schering, Elan,
and Others (includes corresponding Graph/Chart) 33
Multiple Sclerosis Drug Pipeline - An Overview 34
Drugs Under Development for Treating Multiple Sclerosis 34
Fingolimod (Gilenya) 34
Mylinax 34
Laquinimod 35
Campath (Alemtuzumab) 35
Teriflunomide 36
Fampridine-SR 36
BG-12 (Oral Fumarate) 36
MN-166 37
Psoriasis 37
Prevalence 37
Available Treatment Options 38
Biological Drugs 38
Biological Drugs Lead the Fray 39
Potential Therapeutic Products 39
Inflammatory Bowel Diseases 40
Crohn's disease 40
Stages of the Disease 40
Prevalence 40
Diagnosis 41
Treatment 41
Ulcerative Colitis 42
Diagnosis and Treatment 42
Other Diseases 43
Systemic Lupus Erythematosus (SLE) 43
Prevalence and Epidemiology 43
Treatment 43
Sjogren's Syndrome 44
Prevalence and Epidemiology 45
Diagnosis and Treatment 45
Type-1 Diabetes Mellitus 46
Types of Diabetes Mellitus 46
Type 1 or Insulin Dependent Diabetes Mellitus 46
Type 2 or Non-Insulin Dependent Diabetes Mellitus 46
Insulin - Vital for Blood Glucose Management 46
Etiology 46
Prevalence 47
Diabetes in Children - A Growing Concern 47
Diagnosis and Treatment 47
Autoimmune Hepatitis 48
Disease Categories 48
Treatment 48
Side Effects 48
Juvenile Rheumatoid Arthritis 49
Symptoms 49
Diagnosis 49
Scleroderma 49
Prevalence 50
Etiology 50
Diagnosis 50
Management 50
Vasculitis Syndeomes 51
Haematologic Autoimmune Diseases 51
Ankylosing Spondylitis 51

6. CLINICAL TRIALS & RESEARCH STUDIES 52
Antares Pharma Commences VIBEX MTX Clinical Trial for Treating
Rheumatoid Arthritis 52
Avila Therapeutics Introduces Btk Inhibitor for Treating
Autoimmune Diseases and Cancer 52
Athersys and Angiotech to Conduct MultiStem® Clinical Trial 52
BioMarin Commences Amifampridine Phosphate Clinical Trial for
Treating LEMS 53
TxCell Successfully Completes Trial for Crohn's Disease Cell
Therapy 53
Novartis Releases Phase II Data for AIN457 53
Sanofi Releases Phase III TEMSO Study Results of Teriflunomide 54
Biogen Achieves Positive Results for BG-12 Drug Trial 54
Innate Therapeutics Commences MIS416 Clinical Trial in
Progressive MS Patients 54
Pfizer Completes Clinical Trials for Tasocitinib 55
Compugen Completes Animal Model Study of CGEN-15001 55
Avila Therapeutics Commences AVL-292 Clinical Trial 56
Horizon Pharma Completes Clinical Trials for LODOTRA® 56
ChemoCentryx Begins Phase 1 Clinical trial for CCX168 57
NYU Langone Medical Center Announces Potential Therapy for
Rheumatoid Arthritis 57
Compugen to Start Preclinical Development for Therapeutic Drugs 57
Avila Therapeutics Begins Phase I Clinical Trial for AVL-292 58
VBL Therapeutics Releases Preclinical Data for VB-201 58
GlaxoSmithKline and Dynavax Select DV1179 for Endosomal TLR
Inhibitor Program 59
Idera Pharmaceuticals Starts Phase 1 Clinical Study of IMO-3100 60
ChemoCentryx Begins Phase I Clinical Study of CCX168 60
VBL Therapeutics Starts Phase II Clinical Study of VB-201 61
ChemoCentryx Begins Phase II Clinical Study of CCX354 62
Neovacs Starts Phase IIa Clinical Study of TNF Kinoid 62
Galapagos Begins Phase II Clinical Study of Nanocort 63
Plexxikon Starts Dosing of PLX3397 in Phase I Clinical Study 63

7. PRODUCT INTRODUCTIONS/APPROVALS 65
Horizon Pharma Receives FDA Approval for DUEXIS® 65
Venus Remedies to Launch Trois 65
CNRS/Inserm Researchers Introduce Dendrimer ABP as RA Therapy 65
Food and Drug Monitoring Agency to Approve Tocilizumab for
Commercial Use 66
Novartis Bags EC Approval for Gilenya® 66
Genentech Obtains FDA Approval for ACTEMRA 66
Novartis Gains Approval for Gilenya in Japan 66
Novartis Receives FDA Approval for Gilenya 67
Compugen Discovers and Validates CGEN-15001 Soluble
Recombinant Fusion Protein 67
InNexus Biotechnology Develops IXSCD11a 67
Centocor Ortho Biotech Submits sBLA for Simponi Label Extension 68
Osiris Therapeutics Obtains Orphan Drug Designation for
Prochymal from FDA 68
Immunomedics Obtains US Patent for Immunotherapy 68
Biogen Idec Introduces Monoclonal Antibody Tysabri in India 69
Merck Serono Unveils Pre-Filled Pen RebiDose™ in UK 69
BioMarin Unveils Firdapse™ in European Union 69
Sandoz Introduces Calcipotriene Solution in US 70
Cimzia® Receives FDA Approval for Treating Rheumatoid Arthritis 70
Simponi™ Receives FDA Approval for Treating Rheumatoid Arthritis 70
Novartis Introduces Extavia® for Multiple Sclerosis Treatment
in Denmark & Germany 70
Novartis Bags FDA Approval for Extavia 71
UCB Receives EC Approval for Cimzia 71
Centocor Ortho Biotech Receives FDA Approval for Stelara 71
BioMarin Pharmaceutical Bags FDA’s Orphan Drug Designation 71
Promius Pharma Introduces Scytera™ for Psoriasis Treatment 71
Galderma Receives FDA Approval for Plaque Psoriasis Ointment
Vectical™ 72
Roche Obtains EC Approval for Rheumatoid Arthritis Antibody
RoACTEMRA 72
Viron Therapeutics Obtains US Patents for VT-384, VT-346
Candidates 72
Bayer Schering Pharma Obtains Approval for Betafron® Therapy
from SFDA 72
US Food and Drug Administration Approves Certolizumab Pegol 73
Nitec Unveils Lodotra® in Germany 73

8. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST -
A PERSPECTIVE BUILDER 74
HUMIRA® Obtains EU Approval for Polyarticular Juvenile
Idiopathic Arthritis 74
Cimzia® Receives FDA Nod for Treating Crohn’s Disease 74
HUMIRA® Obtains Approval from Japanese Ministry for Rheumatoid
Arthritis 74
HUMIRA® Receives FDA Clerance for Polyarticular Juvenile
Idiopathic Arthritis 74
Abbott Receives EU Marketing Authorization for Humira in
Psoriasis Treatment 75
Xian-Janssen Introduces Remicade, Branded infliximab in China 75
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease 75
HUMIRA® Obtains FDA Approval for Crohn’s Disease 75
Remicade® Obtains Approval for Use in PsA and Early RA in
Australia 76
Tysabri™ Receives Health Canada Approval for Use in Multiple
Sclerosis 76
Rituxan® Gets FDA Approval for Use in RA 76
Humira® Obtains FDA Approval for Treating AS 77
Betaseron® Receives FDA Approval for Use in First Clinical
Episode of MS 77
Abbott Receives FDA Clearance for HUMIRA Pen 78
Remicade Obtains FDA Approval for Treating Pediatric Crohn`s
Disease 78

9. RECENT INDUSTRY ACTIVITY 79
Sanofi-Aventis Takes over Genzyme 79
Daiichi Sankyo to Acquire Plexxikon 79
TiGenix Takes Over Cellerix 79
Alkermes and Elan Drug Technologies to Merge Operations 79
Pfizer Japan Inks Agreements with Takeda to Co-Promote RA Drugs 80
Viropro Inks Letter of Agreement with Spectrum Pharmaceuticals 80
Pepscan Therapeutics Collaborates with Phylogica 81
Lycera Enters into Research Collaboration with Merck 81
Merck Amends Distribution Agreement with Johnson & Johnson 81
Yale University and Debiopharm Enter into License Agreement
for Debio 1036 81
Opexa Therapeutics Inks Agreement with American Red Cross 82
Antitope and NasVax Enter into Research Collaboration 82
SuppreMol Inks In-License Agreement with Bayerische Patentallianz 82
Glenmark Inks License Agreement with Sanofi 83
Exagen Enters into Partnership with Medco 83
Phylogica Inks Research Collaboration and Option Agreement
with Pepscan Therapeutics 84
Merck Sharp & Dohme Enters into Partnership with Lycera 84
Amgen Enters into Collaboration with Xencor 84
PhRMA Announces Development of Medicines Targeted Towards Women 85
Circassia Secures Global Development and Marketing Rights to
PAP-1 from Airmid 85
UCB Establishes Microbial Production Facility 85
Emergent BioSolutions Takes Over Trubion Pharmaceuticals 85
Gilead Sciences to Takeover CGI Pharmaceuticals 86
Abbott Laboratories Acquires Facet Biotech 86
Merck Takes Over Millipore 87
Quidel to Snap Up Diagnostic Hybrids 87
Nitec Pharma Merges with Horizon Therapeutics 87
Femta Pharmaceuticals Inks Manufacturing Agreement with Lonza
Group 87
Horizon Pharma Signs Agreement with Mundipharma International 88
3SBio Signs Agreement with Isotechnika Pharma 88
Fast Forward and Provid Pharmaceuticals Extend Partnership 89
Antitope and PIKAMAB Collaborate 89
Ligon Discovery Enters into Agreement with Lycera 89
Axxam, Fast Forward and Juvenile Diabetes Research Foundation
Enter into Partnership 89
GlaxoSmithKline Collaborates with ChemoCentryx 90
Perseid Signs Agreement with Astellas Pharma for CTLA4-Ig Program 90
Cellceutix Chooses Destum Partners for KM-133 Psoriasis Compound 90
NERC Commences Operations of IXO Therapeutics 91
Avesthagen to Market Avent 91
Isotechnika Pharma Divests Stake in Isodiagnostika 91
MacroGenics Obtains New Grants from NIH 92
AnaptysBio Collaborates with VLST to Generate Novel Antibody
Therapeutics 92
AstraZeneca Enters into Exclusive License Agreement with Rigel
Pharmaceuticals 92
Immutep Inks License Agreement with GlaxoSmithKline for
Therapeutic Antibody IMP731 92
Novo Nordisk Inks Research Collaboration Agreement with Combine 93
Xention and Axxam Enter into Autoimmune Disorder Research
Partnership 93
Roche Takes Over Genentech 93
Merck Acquires Schering-Plough 94
Pfizer Takes Over Wyeth 94
Amgen Takes Over Immunex 94
BioMarin Pharmaceutical Takes Over Huxley Pharmaceuticals 94
Onyx to Takeover Proteolix 95
Genzyme Takes Over Global Rights of Campath, Leukine and
Fludara from Bayer 95
Bristol-Myers Squibb Enters into Agreement with Alder
Biopharmaceuticals 95
LEO Pharma Inks Agreement with Warner Chilcott 95
Kineta One Acquires Commercial Rights for Compounds from Airmid 96
Kineta Signs Agreement with Alturas Analytics 96
Catalyst Biosciences in Research and License Agreement with
MedImmune 96
Boehringer Ingelheimes Collaborates with Exelixis 97
Lonza Signs Agreement with Opsona Therapeutics for
Manufacturing Antibody 97
Eli Lilly and Incyte Enter into Agreement 97
Novartis Option Fund and Avila Therapeutics Sign Option Agreement 97
Genentech Acquires Rights for BHT-3021 from Bayhill Therapeutics 98
Celentyx and Meiji Seika Kaisha Ink Agreement 98
Exelixis and Boehringer Ingelheim Enter into Autoimmune
Disease Partnership 98
Celldex Acquires Exclusive Rights of Immune-Stimulatory
Molecules from Amgen 98
Apitope and Merck Serono Sign Agreement for Multiple Sclerosis
Drug 99
Biovitrum and Affibody® Enter into Collaboration 99
Bayhill Therapeutics Bags Contract from Genentech 99

10. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER 100
Novo Nordisk and VLST Collaborate on Therapeutic Targets
Development 100
Actemra’s Approval Gets Delayed 100
Apitope Raises Financing for Developing Multiple Sclerosis
Compound 101
CalciMedica to Acquire Rights to STIM1 from TorreyPines 101
Roche Acquires ARIUS Research, Inc. 102
Astellas Inks Agreement with Maxygen for MAXY-4 Candidates 102
Carna and Caliper Life Sciences Ink Collaborative Supply
Agreement 103
Isotechnika Gets Back Worldwide Rights to Transplant Drug,
Voclosporin 104
Boehringer In-licenses Two Drug Targets from BioFocus 104
Bionomics Enters into a Development and Licensing Agreement
with Merck Serono 104
Nycomed Inks Agreement with Immunomedics for Veltuzumab 105
EpiVax Receives Grants from National Institutes of Health to
Advance Epi-13 105
Boehringer to Takeover Actimis 106
Antisoma Acquires Xanthus Pharmaceuticals 106
Merrimack Acquires Funds for Developing Cancer and Autoimmune
Disease Biologics 107
BioSeek and Merck Sign Collaboration Agreement for Compound
Evaluation 107
Questcor Amends Distribution Contract with US Distributor of
Acthar 107
ANP Completes Phase IIa Trial for Multiple Sclerosis Drug 108
Insert and Calando Merge to Form Calando Pharmaceuticals 108
Codon Inks Research & Development and Licensing Deal with
Merrimack 108
Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK
Peptide 109
Chelsea Acquires Global Rights to I-3D Range of DHODH
Inhibiting Compounds 109
Cypress Bioscience Acquires Proprius 110
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals 110
GlaxoSmithKline Acquires License to Market Vaccinex’s Antibody 110
Teva to Takeover CoGenesys 111
Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune
Diseases 111
Anthera Acquires Rights to Develop and Market AMG 623 from Amgen 111
Can-Fite Enters into Two Cooperation Agreements to Develop
CF102 Drug 111
Source MDx Inks an Agreement with Pfizer 112
Cambridge Inks an Antibody Development Agreement with Medarex 112
Pfizer to Acquire Coley Pharma 112
GSK Joins Hands with Tolerx to Develop and Commercialize
otelixizumab 113
Amgen Acquires Avidia 114
Eli Lilly and MacroGenics Tie Up for Developing Teplizumab 114
MorphoSys and Genesis Ink Antibody R&D Deal 115
arGentis Enters into a License Agreement with UTRF 115
Eden Biodesign to Investigate Novel Drug Candidate for
Autoimmune Diseases 115
Nuon and Kissei Team up for Tranilast 116
Organon and Dyax Team Up for Developing Therapeutic Antibodies 116
Medarex Joins Hands with Mitsubishi for Monoclonal Antibody
Development 116
Merck and Archemix Collaborate 116
Genzyme Takes Over Bioenvision 117
Organon and Medarex Ink Drug Development Deal 117
CalciMedica Secures Exclusive Rights for CBR’s Autoimmune Drug
Target 117
Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway 118
Eisai Corporation Acquires Morphotek 118
TIRC Changes Name to Orchestra Therapeutics 119
Abbott Files HUMIRA® for Psoriasis in the US and EU (USA/Europe) 119
Accentia Secures Exclusive Global Rights to Revimmune 120
Medarex and Compugen Ink Collaborative Agreement for
Therapeutic Antibody 120
SRI and Telik Sign License Agreement for Drug Development 121
China Biopharma Signs Agreement with Chinese Biopharmaceutical
Firm 122
Kirin and Astellas Ink Licensing Agreement for Anti-CD40
Antagonistic mAb 122
QSV and Artielle Sign Contract to Produce RTL-1000 123
JDRF and MacroGenics Form Partnership 123
GSK and Genmad Sign Partnership Agreement for HuMaxCD20 124
Biocon Enters into Joint Venture Agreement with Neopharma 124
Pipex Pharmaceuticals Acquires Remaining Stake in Effective
Pharmaceuticals 125
Astellas Acquires Worldwide Rights for Amevive® 125
Biogen Acquires Fumapharm 125
Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy 126

11. FOCUS ON SELECT GLOBAL PLAYERS 127
Abbott Laboratories (USA) 127
Amgen Inc. (USA) 127
Bayer Schering Pharma AG (Germany) 128
Biogen Idec Inc. (USA) 129
Bristol-Myers Squibb Company (USA) 130
Elan Corporation plc (Ireland) 130
Eli Lilly and Company (USA) 131
F. Hoffmann-La Roche AG (Switzerland) 132
Chugai Pharmaceutical Co., Ltd. (Japan) 133
Genentech, Inc. (USA) 134
GlaxoSmithKline Plc (UK) 135
Johnson & Johnson, Inc. (USA) 136
Merck & Co., Inc. (US) 136
Merck Serono SA (Switzerland) 137
Novartis AG (Switzerland) 137
Sanofi-aventis SA (France) 138
Shire Plc (Ireland) 139
Teva Pharmaceuticals Industries Limited (Israel) 139
UCB S.A. (Belgium) 140

12. GLOBAL MARKET PERSPECTIVE 141
Table 5: World Recent Past, Current & Future Analysis for
Autoimmune Disease Therapeutics by Geographic Region - US,
Japan, Europe and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2009
through 2017 (includes corresponding Graph/Chart) 141

Table 6: World Historic Review for Autoimmune Disease
Therapeutics by Geographic Region - US, Japan, Europe and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 142

Table 7: World 15-year Perspective for Autoimmune Disease
Therapeutics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe and Rest of World Markets
for Years 2003, 2010 & 2017 (includes corresponding
Graph/Chart) 143

Table 8: World Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics (Biologics) by Geographic
Region - US, Japan, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 144

Table 9: World Historic Review for Rheumatoid Arthritis
Therapeutics (Biologics) by Geographic Region - US, Japan,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 145

Table 10: World 15-year Perspective for Rheumatoid Arthritis
Therapeutics (Biologics) by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Japan, Europe and Rest of
World Markets for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 146

Table 11: World Recent Past, Current & Future Analysis for
Multiple Sclerosis Therapeutics by Geographic Region - US,
Japan, Europe and Rest of World- Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) 147

Table 12: World Historic Review for Multiple Sclerosis
Therapeutics by Geographic Region - US, Japan, Europe and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 148

Table 13: World 15-year Perspective for Multiple Sclerosis
Therapeutics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe and Rest of World Markets
for Years 2003, 2010 & 2017 (includes corresponding
Graph/Chart) 149

Table 14: World Recent Past, Current & Future Analysis for
Psoriasis Therapeutics by Geographic Region - US, Japan,
Europe and Rest of World- Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) 150

Table 15: World Historic Review for Psoriasis Therapeutics by
Geographic Region - US, Japan, Europe and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 151

Table 16: World 15-year Perspective for Psoriasis Therapeutics
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Japan, Europe and Rest of World Markets for Years
2003, 2010 & 2017 (includes corresponding Graph/Chart) 152

Table 17: World Recent Past, Current & Future Analysis for
Crohn’s Disease Therapeutics (Biologicals) by Geographic
Region - US, Japan, Europe and Rest of World- Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 153

Table 18: World Historic Review for Crohn’s Disease
Therapeutics (Biologicals) by Geographic Region - US, Japan,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 154

Table 19: World 15-year Perspective for Crohn’s Disease
Therapeutics (Biologicals) by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Japan, Europe and Rest of
World Markets for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 155

Table 20: World Recent Past, Current & Future Analysis for
Other Autoimmune Disease Therapeutics by Geographic Region -
US, Japan, Europe and Rest of World- Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) 156

Table 21: World Historic Review for Other Autoimmune Disease
Therapeutics by Geographic Region - US, Japan, Europe and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 157

Table 22: World 15-year Perspective for Other Autoimmune
Disease Therapeutics by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Japan, Europe and Rest of
World Markets for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 158

13. THE UNITED STATES 159
A.Market Analysis 159
Current and Future Analysis 159
Autoimmune Diseases Fact Sheet 159
Table 23: Prevalence of Key Autoimmune Diseases in the US
(in Millions) (includes corresponding Graph/Chart) 160
Market Trends 160
Biologic Drugs Lead the Fray 160
Biologics To Add Further Impetus to the Market 160
Rheumatoid Arthritis Drugs Lead the Market 161
Enbrel and Humira Continue to Gain Share in the Anti-TNF
Market 161
Increased Incidence and Rise in Drug Prices to Drive Growth
in MS Market 161
Table 24: Leading Multiple Sclerosis Drugs in the US
(2008): Percentage Share Breakdown of New Prescriptions
Written for Avonex, Copaxone, Rebif, Betaseron, and
Tysabri (includes corresponding Graph/Chart) 162
Incidence of Type 1 Diabetes Mellitus Endemic in White Youth 162
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs
Market 162
Key Ulcerative Colitis Drugs Market in the US (2006) 163
Product Launches/Approvals 163
Strategic Corporate Developments 170
Key Players 202
B.Market Analytics 209
Table 25: US Recent Past, Current & Future Analysis for
Autoimmune Disease Therapeutics by Disease Segment -
Rheumatoid Arthritis (Biologics), Multiple Sclerosis,
Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune
Diseases Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 209

Table 26: US Historic Review for Autoimmune Disease
Therapeutics by Disease Segment - Rheumatoid Arthritis
(Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease
(Biologics) and Other Autoimmune Diseases Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) 210

Table 27: US 15-Year Perspective for Autoimmune Disease
Therapeutics by Disease Segment - Percentage Breakdown of
Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple
Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other
Autoimmune Diseases for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 211

14. JAPAN 212
A.Market Analysis 212
Current and Future Analysis 212
Japanese Patients Exhibit Unique Efficacy & Safety Effects 212
Product Launches/Approvals 212
Strategic Corporate Developments 213
Key Players 214
B.Market Analytics 215
Table 28: Japanese Recent Past, Current & Future Analysis
for Autoimmune Disease Therapeutics by Disease Segment -
Rheumatoid Arthritis (Biologics), Multiple Sclerosis,
Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune
Diseases Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 215

Table 29: Japanese Historic Review for Autoimmune Disease
Therapeutics by Disease Segment - Rheumatoid Arthritis
(Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease
(Biologics) and Other Autoimmune Diseases Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) 216

Table 30: Japanese 15-Year Perspective for Autoimmune
Disease Therapeutics by Disease Segment - Percentage
Breakdown of Dollar Sales for Rheumatoid Arthritis
(Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease
(Biologics) and Other Autoimmune Diseases for Years 2003,
2010 & 2017 (includes corresponding Graph/Chart) 217

15. EUROPE 218
A.Market Analysis 218
Current and Future Analysis 218
Europe - A Burgeoning Market for Autoimmune Disease
Therapeutics 218
Increasing Awareness to Drive Market Growth 218
Low Penetration to Fuel Growth in European MS DMDs Market 218
Table 31: Prevalence of Key Autoimmune Diseases in Europe
in Millions (includes corresponding Graph/Chart) 219
Lower Treatment Rate Bodes Huge Potential for the UK MS Drug
Market 219
Drugs Hindering Disease Progression to Gain Prominence 219
Rising Demand for Rheumatoid Arthritis Drugs in Russia 219
Product Launches/Approvals 220
Strategic Corporate Developments 224
Key Players 234
B.Market Analytics 241
Table 32: European Recent Past, Current & Future Analysis
for Autoimmune Disease Therapeutics by Disease Segment -
Rheumatoid Arthritis (Biologics), Multiple Sclerosis,
Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune
Diseases Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 241

Table 33: European Historic Review for Autoimmune Disease
Therapeutics by Disease Segment - Rheumatoid Arthritis
(Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease
(Biologics) and Other Autoimmune Diseases Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) 242

Table 34: European 15-Year Perspective for Autoimmune
Disease Therapeutics by Disease Segment - Percentage
Breakdown of Dollar Sales for Rheumatoid Arthritis
(Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease
(Biologics), and Other Autoimmune Diseases for Years 2003,
2010 & 2017 (includes corresponding Graph/Chart) 243

16. REST OF WORLD 244
A.Market Analysis 244
Current and Future Analysis 244
Canada 244
Canada - Highest Prevalence Rates for Multiple Sclerosis 244
Sales of Biologics on the Rise in Canadian Rheumatoid
Arthritis Drugs Market 244
Asia-Pacific 245
Autoimmune Diseases Market in Asia-Pacific - An Overview 245
Incidence of Multiple Sclerosis in India on the Rise 245
Overview of Rheumatoid Arthritis in Australia 246
Table 35: Percentage Breakdown of Prevalence of
Rheumatoid Arthritis in Australia by Age Group (includes
corresponding Graph/Chart) 246

Table 36: Percentage Breakdown of Prevalence of
Rheumatoid Arthritis in Australia by Sex (includes
corresponding Graph/Chart) 247
Overview of Irritable Bowel Diseases in Australia 247
Product Launches/Approvals 248
Strategic Corporate Developments 250
Key Player 255
B.Market Analytics 256
Table 37: Rest of World Recent Past, Current & Future
Analysis for Autoimmune Disease Therapeutics by Disease
Segment - Rheumatoid Arthritis (Biologics), Multiple
Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other
Autoimmune Diseases Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 256

Table 38: Rest of world Historic Review for Autoimmune
Disease Therapeutics by Disease Segment - Rheumatoid
Arthritis (Biologics), Multiple Sclerosis, Psoriasis,
Crohn’s Disease (Biologics) and Other Autoimmune Diseases
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 257

Table 39: Rest of World 15-Year Perspective for Autoimmune
Disease Therapeutics by Disease Segment - Percentage
Breakdown of Dollar Sales for Rheumatoid Arthritis
(Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease
(Biologics) and Other Autoimmune Diseases for Years 2003,
2010 & 2017 (includes corresponding Graph/Chart) 258


COMPETITIVE LANDSCAPE

Total Companies Profiled: 112 (including Divisions/Subsidiaries - 124)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 77
Canada 9
Japan 3
Europe 27
France 1
Germany 7
The United Kingdom 7
Rest of Europe 12
Asia-Pacific (Excluding Japan) 6
Middle East 2
------------------------------------------